Tag archive for ‘MAP Pharmaceuticals Inc.’
Investment Implications of the Acquisition of MAP Pharmaceuticals by Allergan
Allergan to Acquire MAP Pharmaceuticals Allergan (AGN) has announced that it will acquire MAP Pharmaceuticals (MAPP) at a price of $25 per share which represents a 60% premium over the closing price of $15.58 on Tuesday, the day before the deal was announced. This values MAPP at just under $1 billion. The deal was obviously […]
Levadex Receives Complete Response Letter, What Does This Mean for the Stock? (MAPP, $16.44)
Summary I think that it is a question of when and not if Levadex is approved. The complete response letter or CRL issued for Levadex appears to be resolvable fairly quickly and could result in approval in July to October of 2012 in my best case scenario. In the worst case, I estimate that approval […]
Levadex Has a Good Chance for Approval on its March 26th PDUFA Date (MAPP, $17.09)
Investment Opinion, In Brief The PDUFA date for Levadex, MAP Pharmaceutical’s lead product, is looming on March 26, 2012. I believe that there is a very high probability for approval and only a small chance for a Complete Response Letter. A CRL, if issued, would likely relate to the Chemical, Manufacturing and Control (CMC) section […]
Initiating Coverage of MAP Pharmaceuticals with A Buy Based On Potential for Levadex (MAPP, $13.35)
Investment Opinion Map Pharmaceuticals is poised to introduce its first commercial product, Levadex (inhaled dihydroergotamine) that is indicated for treating acute migraine attacks. I consider Levadex to be a very important new drug with significant commercial potential. The PDUFA date is March 26, 2012. Triptans (Imitrex, Axert, Frova, Maxalt, Relpax, Treximet and Zomig) are […]